Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2000 3
2001 3
2002 3
2003 1
2004 5
2005 4
2006 3
2007 7
2008 9
2009 16
2010 11
2011 5
2012 8
2013 8
2014 15
2015 7
2016 6
2017 4
2018 5
2019 5
2020 4
2021 6
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

130 results
Results by year
Filters applied: . Clear all
Page 1
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
Berzero G, Di Stefano AL, Ronchi S, Bielle F, Villa C, Guillerm E, Capelle L, Mathon B, Laurenge A, Giry M, Schmitt Y, Marie Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M. Berzero G, et al. Among authors: marie y. Neuro Oncol. 2021 Jun 1;23(6):955-966. doi: 10.1093/neuonc/noaa258. Neuro Oncol. 2021. PMID: 33173941 Free PMC article.
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network. Appay R, et al. Among authors: marie y. Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124. Neuro Oncol. 2019. PMID: 31832685 Free PMC article.
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A. Di Stefano AL, et al. Among authors: marie y. Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609060 Free PMC article. Clinical Trial.
Antiglycolipid antibodies in motor neuropathies.
Baumann N, Harpin ML, Marie Y, Lemerle K, Chassande B, Bouche P, Meininger V, Yu RK, Léger JM. Baumann N, et al. Among authors: marie y. Ann N Y Acad Sci. 1998 Jun 19;845:322-9. doi: 10.1111/j.1749-6632.1998.tb09684.x. Ann N Y Acad Sci. 1998. PMID: 9668365 Review.
NFKBIA deletion in glioblastomas.
Idbaih A, Marie Y, Sanson M. Idbaih A, et al. Among authors: marie y. N Engl J Med. 2011 Jul 21;365(3):277; author reply 277-8. doi: 10.1056/NEJMc1103354. N Engl J Med. 2011. PMID: 21774727 No abstract available.
OLIG-1 and 2 gene expression and oligodendroglial tumours.
Hoang-Xuan K, Aguirre-Cruz L, Mokhtari K, Marie Y, Sanson M. Hoang-Xuan K, et al. Among authors: marie y. Neuropathol Appl Neurobiol. 2002 Apr;28(2):89-94. doi: 10.1046/j.1365-2990.2002.00395.x. Neuropathol Appl Neurobiol. 2002. PMID: 11972795 Review.
Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma.
Verreault M, Segoviano Vilchis I, Rosenberg S, Lemaire N, Schmitt C, Guehennec J, Royer-Perron L, Thomas JL, Lam TT, Dingli F, Loew D, Ducray F, Paris S, Carpentier C, Marie Y, Laigle-Donadey F, Rousseau A, Pigat N, Boutillon F, Bielle F, Mokhtari K, Frank SJ, de Reyniès A, Hoang-Xuan K, Sanson M, Goffin V, Idbaih A. Verreault M, et al. Among authors: marie y. Clin Transl Med. 2022 Jul;12(7):e939. doi: 10.1002/ctm2.939. Clin Transl Med. 2022. PMID: 35808822 Free PMC article.
130 results